---
title: "Bell Potter 維持對 Telix Pharmaceuticals (TLPPF) 的買入評級"
description: "根據 TipRanks 的數據，Hester 是一位四星分析師，平均回報率為 11.8%，成功率為 55.56%。Hester 覆蓋醫療保健行業，關注的股票包括 Telix Pharmaceuticals、Sigma Healthcare Ltd 和 Mesoblast Limited。除了 Bell Potter，Telix Pharmaceuticals 還在 9 月 23 日的報告中獲得了摩"
type: "news"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/259219939.md"
published_at: "2025-09-28T14:05:06.000Z"
---

# Bell Potter 維持對 Telix Pharmaceuticals (TLPPF) 的買入評級

> 根據 TipRanks 的數據，Hester 是一位四星分析師，平均回報率為 11.8%，成功率為 55.56%。Hester 覆蓋醫療保健行業，關注的股票包括 Telix Pharmaceuticals、Sigma Healthcare Ltd 和 Mesoblast Limited。除了 Bell Potter，Telix Pharmaceuticals 還在 9 月 23 日的報告中獲得了摩根士丹利的 David Bailey 的買入評級。然而，在 9 月 24 日，TR | OpenAI – 4o 對 Telix Pharmaceuticals（其他場外交易：TLPPF）重申了持有評級

根據 TipRanks 的數據，Hester 是一位 4 星分析師，平均回報率為 11.8%，成功率為 55.56%。Hester 覆蓋醫療保健行業，專注於 Telix Pharmaceuticals、Sigma Healthcare Ltd 和 Mesoblast Limited 等股票。

除了 Bell Potter，Telix Pharmaceuticals 還在 9 月 23 日的報告中獲得了摩根士丹利的 David Bailey 的買入評級。然而，在 9 月 24 日，TR | OpenAI – 4o 對 Telix Pharmaceuticals（其他場外交易：TLPPF）重申了持有評級。

### Related Stocks

- [TLX.US - Telix Pharmaceuticals](https://longbridge.com/zh-HK/quote/TLX.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Telix Full Year Results 2025 Investor Webcast Notification \| TLX Stock News | Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX) will release its full year results for 2025 on February 20, 2026,  | [Link](https://longbridge.com/zh-HK/news/274715952.md) |
| Australia's Telix Pharma falls to over 2-year low as chair resigns | ** Shares of Australia's Telix Pharmaceuticals down 7.3% so far this week, set for their steepest weekly drop since the  | [Link](https://longbridge.com/zh-HK/news/275068806.md) |
| Medexus Pharmaceuticals reports Q3 results | Medexus Pharmaceuticals reports Q3 results | [Link](https://longbridge.com/zh-HK/news/275670725.md) |
| Ampersand Capital Partners Acquires Purna Pharmaceuticals | Ampersand Capital Partners has acquired Purna Pharmaceuticals, a provider of development and manufacturing services for  | [Link](https://longbridge.com/zh-HK/news/275752992.md) |
| Apimeds Pharmaceuticals and Lōkahi Therapeutics Announce FDA Type C Meeting Scheduled for LT‑100 (Apitox) \| APUS Stock News | Apimeds Pharmaceuticals and Lōkahi Therapeutics announced a Type C meeting with the FDA to discuss LT-100 (Apitox), a no | [Link](https://longbridge.com/zh-HK/news/275664271.md) |

---

> **免責聲明**：本文內容僅供參考，不構成任何投資建議。